Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
Vaccines.
3.ª,
[2.]
Committe on immunization, fiance, policies and practices.
Calling the shots. Immunization, fiance, policies and practice.
[3.]
B. Guyer, D.R. Smith, R. Chalk.
Calling the shots: immunization finance policies and pratices.
Am J Prev Med, 19 (2000), pp. 4-11
[4.]
Vacunaciones preventivas. Principios y aplicaciones.
[5.]
L. Salleras, A. Domínguez, J. Batalla, J.M. Corretger, F. Moraga, J. Roca, et al.
L'eliminació del xarampió a Catalunya per a l'any 2000 Bases científiques i programa.
[6.]
L. Salleras, A. Domínguez, G. Prats.
Control of serogroup C meningococcal disease by mass vaccination in Catalonia (Spain).
Vaccine, 17 (1999), pp. 556-560
[7.]
J.A. Navarro Alonso, P.J. Bernal González.
Calendarios vacunales y enfermedades inmunoprevenibles en países de Europa occidental.
Vacunas Invest Pract, 1 (2000), pp. 48-54
[8.]
Dirección General de Salud Pública.
Ministerio de Sanidad y Consumo. Calendario de vacunaciones 2001.
Bol Epidemiol Sem, 8 (2000), pp. 266-267
[9.]
D.R. Smith.
Immunization in the new millennium. Meeting the challenge to realize the promise.
Am J Prev Med, 19 (2000), pp. 1-3
[10.]
Centers for Disease Control and Prevention.
Vaccine-preventable diseases: improving vaccination coverage in children, adolescents, and adults.
MMWR, 48 (1999), pp. 1-15
[11.]
L. Salleras, L. Urbiztondo, N. Fernández, E. Comín, F. Sánchez, J. Batalla, et al.
Vacunación antineumocócica en las personas mayores.
Med Clin (Barc), 116 (2001), pp. 18-23
[12.]
J.L. Taberner, J. Vidal, A. Domínguez, M.A. Mayer, J. Vaqué, L. Salleras.
Vacunación antigripal en las personas mayores.
Med Clin (Barc), 116 (2001), pp. 24-26
[13.]
M.M. Levine, O.S. Levine.
Influence of disease burden, public perception and others factors on new vaccine development, implementation and continued use.
Lancet, 350 (1997), pp. 1386-1392
[14.]
B. Aylaward, K.A. Hennessey, N. Zagaria, J.M. Olivé, S. Cochi.
When is a disease eradicable?.
100 years of lessons learned. Am J Public Health, 90 (2000), pp. 1515-1520
[15.]
B.J. Ward.
Vaccine adverse events in the new millennium: is there reason for concern.
Bull WHO, 78 (2000), pp. 206-215
[16.]
Centers for Disease Control and Prevention.
Intussusception among recipients of rotavirus vaccine -United States, 1998–1999.
JAMA, 282 (1999), pp. 520-521
[17.]
B.G. Gellin, W.W. Schaffner.
The risk of vaccination -the importance of «negative» studies.
N Engl J Med, 344 (2001), pp. 372-373
[18.]
E. Álvarez, R. Génova, C. Amela, I. Pachón.
Denominador en el cálculo de coberturas de vacunación en España.
Bol Epidemiol Sem, 8 (2000), pp. 241-244
[19.]
G. Fairbrother, G.L. Freed, J.W. Thompson.
Measuring immunization coverage.
Am J Prev Med, 19 (2000), pp. 78-88
[20.]
J.L. Aboal Viñas, P. Fargas Abadía, R. Zubizarreta Alberdi, X. Hervada Vidal, A. Malvar Pintos, M. Amigo Quintana, et al.
El procedimiento de toma de decisión para controlar la epidemia de menigitis C en Galicia en 1996.
Gac Sanit, 13 (1999), pp. 62-69
[21.]
J. Esparza, N. Bhamarapravati.
Accelerating the development and future availability of HIV-1 vaccines: why, where and how.
Lancet, 355 (2000), pp. 2061-2066
[22.]
Vaccine for the 21st century: a tool for decisionmaking.
[23.]
W.A. Orenstein.
Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination.
Clin Infect Dis, 28 (1999), pp. S147-S150
[24.]
B. Swennen, J. Levy.
Oral poliomyelitis vaccine: time to change?.
Vaccine, 19 (2001), pp. 2262-2267
[25.]
Centers for Disease Control and Prevention.
Prevention of varicella. Update recommendations of the advisory committee on immunization practices (ACIP).
MMWR, 48 (1999), pp. 1-5
[26.]
A.M. Arvin.
Varicella vaccine -the first six years.
N Engl J Med, 344 (2001), pp. 1007-1009
[27.]
K.A. Robinson, W. Baughman, G. Rothrock, N. Barrett, M. Pass, C. Lexau, et al.
Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998 Opportunities for prevention in the conjugate vaccine era.
JAMA, 285 (2001), pp. 1729-1735
[28.]
Centers for Disease Control and Prevention.
Preventing pneumococcal disease among infants and young children. Recommendations of the advisory committee on immunization practices (ACIP).
MMWR, 49 (2000), pp. 1-35
[29.]
J. Eskola, T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, et al.
Efficacy of a pneumococcal conjugate vaccine against acute otitis media.
N Engl J Med, 344 (2001), pp. 403-409
[30.]
T.A. Reichert, N. Sugaya, D. Fedson, P. Glezen, L. Simonsen, M. Tashiro.
The Japanese experience vaccinating schoolchildren against influenza.
N Engl J Med, 344 (2001), pp. 889-896
[31.]
K. McIntosh, T. Lieu.
Is it time to give influenza vaccine to healthy infants.
N Engl J Med, 342 (2000), pp. 275-276
[32.]
R.B. Belshe, P.M. Mendelman, J. Treanor, J. King, W.C. Gruber, P. Piedra, et al.
The efficecy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
N Engl J Med, 338 (1998), pp. 1405-1412
Copyright © 2001. Sociedad Española de Salud Pública y Administración Sanitaria
